Get to know our clinical trials

Randomized, double-masked, controlled study to evaluate the safety and tolerability of VRDN-003 in participants with thyroid eye disease (TOD).

THE PURPOSE OF THE STUDY, WHICH INVOLVES RESEARCH, IS TO DETERMINE WHETHER VRDN-003, THE EXPERIMENTAL INVESTIGATIONAL DRUG, IS SAFE AND TOLERABLE (I.E., WHETHER THE BODY REACTS ACCEPTABLY TO VRDN-003) IN PARTICIPANTS WITH EOT WHEN ADMINISTERED AS A SERIES OF SUBCUTANEOUS (SC) INJECTIONS (GIVEN BY NEEDLE INTO THE LAYER OF FAT BETWEEN THE SKIN AND MUSCLE).

Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • RANDOMIZED, DOUBLE-MASKED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF VRDN-003 IN PARTICIPANTS WITH THYROID EYE DISEASE (TOD).
  • Code EudraCT: 2024-519417-57-00
  • Protocol number: VRDN-003-303
  • Promoter: Viridian Therapeutics, Inc
  • Molecule/Drug: VRDN-003
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.